	TEST	REPORT	
Reg. No : 2202101130			Reg. Date : 12-Feb-2022
Name : Rekha Verma			Collected On : 12-Feb-2022 10:43
Age/Sex : 37 Years / Female			Approved On : 12-Feb-2022 17:30
Ref. By			Printed On : 08-Mar-2022 14:56
Client : MEDIWHEEL WELLNESS			
Parameter	<u>Result</u>	<u>Unit</u>	Reference Interval
	KIDNEY FU	JNCTION TEST	
UREA (Urease & glutamate dehydrogenase)	KIDNEY FL 21.7	JNCTION TEST	10 - 50
-			10 - 50 0.5 - 1.2

----- End Of Report -----

This is an electronically authenticated report.

Page 1 of 11

Approved by: DR

TEST REPORT

Reg. No:2202101130Name:Rekha VermaAge/Sex:37 Years / FemaleRef. By:Client:MEDIWHEEL WELLNESS

 Reg. Date
 : 12-Feb-2022

 Collected On
 : 12-Feb-2022 10:43

 Approved On
 : 12-Feb-2022 11:39

 Printed On
 : 08-Mar-2022 14:56

Parameter	Result	<u>Unit</u>	Reference Interval			
COMPLETE BLOOD COUNT (CBC)						
SPECIMEN: EDTA BLOOD						
Hemoglobin	13.9	g/dL	12.0 - 15.0			
RBC Count	4.68	million/cmm	3.8 - 4.8			
Hematrocrit (PCV)	44.3	%	40 - 54			
MCH	29.7	Pg	27 - 32			
MCV	94.7	fL	83 - 101			
MCHC	31.4	%	31.5 - 34.5			
RDW	12.8	%	11.5 - 14.5			
WBC Count	9160	/cmm	4000 - 11000			
DIFFERENTIAL WBC COUNT (Flow	<u>cytometry)</u>					
Neutrophils (%)	54	%	38 - 70			
Lymphocytes (%)	40	%	20 - 40			
Monocytes (%)	04	%	2 - 8			
Eosinophils (%)	02	%	0 - 6			
Basophils (%)	00	%	0 - 2			
Neutrophils	4946	/cmm				
Lymphocytes	3664	/cmm				
Monocytes	366	/cmm				
Eosinophils	183	/cmm				
Basophils	0	/cmm				
Platelet Count (Flow cytometry)	276000	/cmm	150000 - 450000			
MPV	8.5	fL	7.5 - 11.5			
ERYTHROCYTE SEDIMENTATION F	RATE					
ESR (After 1 hour)	15	mm/hr	0 - 21			
Modified Westergren Method						

----- End Of Report ------

Page 2 of 11

This is an electronically authenticated report.



		TEST REPORT	
Reg. No	: 2202101130	Reg. Date	: 12-Feb-2022
Name	: Rekha Verma	Collected On	: 12-Feb-2022 10:43
Age/Sex	: 37 Years / Female	Approved On	: 12-Feb-2022 11:39
Ref. By	:	Printed On	: 08-Mar-2022 14:56
Client	: MEDIWHEEL WELLNESS		
Paramet	er	<u>Result</u>	
		BLOOD GROUP & RH	
	Specimen	: EDTA and Serum; Method: Haemagglutination	
ABO	Specimen	: EDTA and Serum; Method: Haemagglutination 'B'	
ABO	Specimen	· ••	

----- End Of Report ------

This is an electronically authenticated report.

Page 3 of 11



		TEST	REPORT	
Reg. No	: 2202101130			Reg. Date : 12-Feb-2022
Name	: Rekha Verma			Collected On : 12-Feb-2022 10:43
Age/Sex	: 37 Years / Female			Approved On : 12-Feb-2022 17:30
Ref. By	:			Printed On : 08-Mar-2022 14:56
Client	: MEDIWHEEL WELLNESS			
Paramet	ter	<u>Result</u>	<u>Unit</u>	Reference Interval
		PLASM	A GLUCOSE	
Fasting Bl Hexokinase	ood Sugar (FBS) ^{Method}	101.0	mg/dL	70 - 110
Or 2. Fasting pl Or 3. Two hour dissolved in Or		defined as no caloric intal an oral glucose tolerence	test by using a glucose l	oad containing equivalent of 75 gm anhydrous glucos

4. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose >/= 200 mg/dL.
 *In the absence of unequivocal hyperglycemia, criteria 1-3 should be confirmed by repeat testing.
 American diabetes association. Standards of medical care in diabetes 2011. Diabetes care 2011;34;S11.

----- End Of Report ------

This is an electronically authenticated report.

Page 4 of 11

TEST REPORT

Reg. No:2202101130Name:Rekha VermaAge/Sex:37 Years / FemaleRef. By:

 Reg. Date
 : 12-Feb-2022

 Collected On
 : 12-Feb-2022 10:43

 Approved On
 : 12-Feb-2022 17:30

 Printed On
 : 08-Mar-2022 14:56

Client : MEDIWHEEL WELLNESS

Printed On	:	08-Ma

Parameter	<u>Result</u>	<u>Unit</u>	Reference Interval			
LIPID PROFILE						
Cholesterol (Enzymatic colorimetric)	203.0	mg/dL	Desirable : < 200.0 Borderline High : 200-239 High : > 240.0			
Triglyceride (Enzymatic colorimetric)	151.1	mg/dL	Normal : < 150.0 Borderline : 150-199 High : 200-499 Very High : > 500.0			
VLDL	30.22	mg/dL	15 - 35			
Calculated						
LDL CHOLESTEROL	142.48	mg/dL	Optimal : < 100.0 Near / above optimal : 100-129 Borderline High : 130-159 High : 160-189 Very High : >190.0			
HDL Cholesterol Homogeneous enzymatic colorime	30.3 tric	mg/dL	30 - 85			
Cholesterol /HDL Ratio Calculated	6.70		0 - 5.0			
LDL / HDL RATIO Calculated	4.70		0 - 3.5			

Page 5 of 11



		Т	EST REPORT		
Reg. No	: 2202101130			Reg. Date	: 12-Feb-2022
Name	: Rekha Verma			Collected On	: 12-Feb-2022 10:43
Age/Sex	: 37 Years / Female			Approved On	: 12-Feb-2022 17:30
Ref. By	:			Printed On	: 08-Mar-2022 14:56
Client	: MEDIWHEEL WEL	LNESS			
Paramete	er	<u>Result</u>	<u>Unit</u>	Reference Interval	

NEW ATP III GUIDELINES (MAY 2001), MODIFICATION OF NCEP<?xml:namespace prefix = "o" ns = "urn:schemasmicrosoft-com:office:office" />

LDL CHOLESTEROL CHOLESTEROL HDL CHOLESTEROL
TRIGLYCERIDES
Optimal<100
Desirable<200
Low<40
Normal<150
Near Optimal 100-129
Border Line 200-239
High >60
Border High 150-199
Borderline 130-159
High >240
-
High 200-499
High 160-189

LDL Cholesterol level is primary goal for treatment and varies with risk category and assessment

For LDL Cholesterol level Please consider direct LDL value •

Risk assessment from HDL and Triglyceride has been revised. Also LDL goals have changed.

Detail test interpreation available from the lab

All tests are done according to NCEP guidelines and with FDA approved kits. •

• LDL Cholesterol level is primary goal for treatment and varies with risk category and assessment # For test performed on specimens received or collected from non-KSHIPRA locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the point generation of the said specimen by the sender.

KSHIPRA will be responsible Only for the analytical part of test carried out. All other responsibility will be of referring Laboratory. . All other responsibility will be of referring Laboratory.

----- End Of Report ------

Page 6 of 11



	TES	T REPORT	
Reg. No : 2202101130 Name : Rekha Verma			Reg. Date : 12-Feb-2022 Collected On : 12-Feb-2022 10:43
Age/Sex : 37 Years / Female Ref. By :			Approved On : 12-Feb-2022 17:30 Printed On : 08-Mar-2022 14:56
Client : MEDIWHEEL WELLNES	S		
Parameter	<u>Result</u>	<u>Unit</u>	Reference Interval
	LIVER F	UNCTION TEST	г
Total Bilirubin Colorimetric diazo method	0.47	mg/dL	0.20 - 1.0
Conjugated Bilirubin Sulph acid dpl/caff-benz	0.18	mg/dL	0.0 - 0.3
Unconjugated Bilirubin Sulph acid dpl/caff-benz	0.29	mg/dL	0.0 - 1.1
SGOT (Enzymatic)	16.1	U/L	0 - 31
SGPT (Enzymatic)	19.0	U/L	0 - 31
Alakaline Phosphatase (Colorimetric standardized method)	77.3	U/L	42 - 141
Protien with ratio			
Total Protein (Colorimetric standardized method)	7.5	g/dL	6.5 - 8.7
Albumin (Colorimetric standardized method)	4.9	mg/dL	3.5 - 4.94

----- End Of Report ------

g/dL

2.3 - 3.5

0.8 - 2.0

2.60

1.88

Page 7 of 11

Globulin

Calculated A/G Ratio

Calculated



	TEST	REPORT			
Reg. No : 2202101130			Reg. Date	: 12-Feb-2022	
Name : Rekha Verma			Collected On	: 12-Feb-2022 10:43	
Age/Sex : 37 Years / Female			Approved On	: 12-Feb-2022 17:30	
Ref. By			Printed On	: 08-Mar-2022 14:56	
Client : MEDIWHEEL WELLNESS					
Parameter	<u>Result</u>	<u>Unit</u>	Reference	e Interval	
	HEMOGLOBIN	A1 C ESTIMAT	ΓΙΟΝ		

Specimen: Blood EDTA

Hb A1C Boronate Affinity with Fluorescent Quenching	5.3	% of Total Hb	Poor Control : > 7.0 % Good Control : 6.2-7.0 % Non-diabetic Level : 4.3-6.2 %
Mean Blood Glucose	111.38	mg/dL	

Degree of Glucose Control Normal Range:

Poor Control >7.0% *

Good Control 6.0 - 7.0 %**Non-diabetic level < 6.0 %

* High risk of developing long term complication such as retinopathy, nephropathy, neuropathy, cardiopathy,etc.

* Some danger of hypoglycemic reaction in Type I diabetics.

* Some glucose intolerant individuals and "subclinical" diabetics may demonstrate HbA1c levels in this area.

EXPLANATION :-

*Total haemoglobin A1 c is continuously symthesised in the red blood cell throught its 120 days life span. The concentration of HBA1c in the cell reflects the average blood glucose concentration it encounters.

*The level of HBA1c increases proportionately in patients with uncontrolled diabetes. It reflects the average blood glucose oncentration over an extended time period and remains unaffected by short-term fluctuations in blood glucose levels. *The measurement of HbA1c can serve as a convenient test for evaluating the adequacy of diabetic control and in preventing various diabetic complications. Because the average half life of a red blood cell is sixty days,HbA1c has been accepted as a measurnment which eflects the mean daily blood glucose concentration, better than fasting blood glucose determination, and the degree of carbohydrate imbalance over the preceding two months.

*It may also provide a better index of control of the diabetic patient without resorting to glucose loading procedures.

HbA1c assay Interferences:

*Errneous values might be obtained from samples with abnormally elevated quantities of other Haemoglobins as a result of either their simultaneous elution with HbA1c(HbF) or differences in their glycation from that of HbA(HbS)

----- End Of Report ------

This is an electronically authenticated report.

Page 8 of 11

DR PS RAO MD Pathologist

	Т	EST REPORT	
Reg. No : 2202101130			Reg. Date : 12-Feb-2022
Name : Rekha Verma			Collected On : 12-Feb-2022 10:43
Age/Sex : 37 Years / Female			Approved On : 12-Feb-2022 14:49
Ref. By : Client : MEDIWHEEL WELLN	ESS		Printed On : 08-Mar-2022 14:56
Parameter	<u>Result</u>	<u>Unit</u>	Reference Interval
	THYRO	DID FUNCTION T	EST
T3 (Triiodothyronine) Chemiluminescence	1.25	ng/mL	0.87 - 1.78
T4 (Thyroxine) Chemiluminescence	7.23	µg/dL	5.89 - 14.9
TSH (ultra sensitive)	2.860	µIU/mI	0.34 - 5.6

Chemiluminescence

SUMMARY The hypophyseal release of TSH (thyrotropic hormone) is the central regulating mechanism for the biological action of thyroid hormones.TSH is a very sensitive and specific parameter for assessing thyroid function and is particularly suitable for early detection or exclusion of disorders in the central regulating circuit between the hypothalamus, pituitary and thyroid. LIMITATION Presence of autoantibodies may cause unexpected high value of TSH

----- End Of Report ------

Page 9 of 11

This is an electronically authenticated report.

	TEST	REPORT	
Reg. No : 2202101130			Reg. Date : 12-Feb-2022
lame : Rekha Verma			Collected On : 12-Feb-2022 10:43
Age/Sex : 37 Years / Female			Approved On : 12-Feb-2022 12:48
Ref. By : Client : MEDIWHEEL WELLNES			Printed On : 08-Mar-2022 14:56
-		11	Defense a lateral
<u>Parameter</u>	Result		Reference Interval
		NE EXAMINATIO	DN
PHYSICAL EXAMINATION	00		
Quantity Colour	20 cc Pale Yellow		
		TDIO METUOD	
CHEMICAL EXAMINATION (BY RE pH	6.0	=	5.0 - 8.0
Sp. Gravity	1.020		1.002 - 1.03
Protein	Nil		
Glucose	Nil		
Ketone Bodies	Nil		
Urine Bile salt and Bile Pigment	Nil		
Urine Bilirubin	Nil		
Nitrite	Nil		
Leucocytes	Nil		
Blood	Nil		
MICROSCOPIC EXAMINATION (MA	NUAL BY MCIROSCOP	<u>Y)</u>	
Leucocytes (Pus Cells)	Nil		
Erythrocytes (Red Cells)	Nil		
Epithelial Cells	1-2/hpf		
Amorphous Material	Nil		
Casts	Nil		
Crystals	Nil		
Bacteria	Nil		
Monilia	Nil		

Page 10 of 11

----- End Of Report ------



		TEST REPORT	TEST REPORT	
Reg. No	: 2202101130	Reg. Date	: 12-Feb-2022 10:43	
Name	: Rekha Verma	Collected On	: 12-Feb-2022 10:43	
Age	: 37 Years / FEMALE	Approved On	: 12-Feb-2022	
Ref. By	:	Printed On	: 12-Feb-2022	
Client	: MEDIWHEEL WELLNESS			

PAP SMEAR

Adequacy	: Satisfactory
Maturity Index	: 00/20/80
Inflammation	:++
Bacilli	:++
RBC	: Absent
Endocervical Cells	: Present
Dysplasia	: NIL

Grade	: II inflammatory.
Bethesda category	: NILM(Negative for Intraepithelial Lesion or Malignancy)

Page 11 of 11

This is an electronically authenticated report.



Approved By : DR PS RAO